Effect of left ventricular hypertrophy on long-term survival of patients with coronary artery disease following percutaneous coronary intervention
Abstract
Overview
The impact of left ventricular hypertrophy
(LVH) on survival among patients with established
coronary artery disease (CAD) is not
well understood. We sought to evaluate the
effect of LVH on the survival of patients with
CAD following percutaneous coronary intervention
(PCI). Three hospitals in New York
City contributed prospectively defined data on
4284 consecutive patients undergoing PCI. Allcause
mortality at a mean follow-up of three
years was the primary endpoint. LVH was present
in 383 patients (8.9%). LVH patients had a
greater prevalence of hypertension (88% vs.
68%, p<0.001), vascular disease (21% vs.
6.6%, p=0.001), and prior heart failure (10%
vs. 5.5%, p<0.001). LVH patients presented
less often with one-vessel disease (38% vs.
50%, p=0.040) and more often with two- (34%
vs. 29%, p=0.014) or three-vessel (22% vs.
18%, p=0.044) disease. Ejection fractions and
angiographic success were similar in both
groups. In-hospital mortality did not differ
between groups. At three-year follow-up, the
survival rate for patients with LVH was 86% vs.
91% in patients without LVH (log-rank
p=0.001). However, after adjustment for differences in baseline characteristics using Cox proportional hazards analysis, LVH was found
not to be an independent predictor of mortality
(hazard ratio, 0.93; 95% confidence interval,
0.68-1.28; p=0.67). We conclude that LVH at
the time of PCI is not independently associated
with an increase in the hazard of death at
three years.
Keywords
Angioplasty, stent, left ventricular hypertrophy, survival.
Article Information
Correspondence
David L. Brown, Division of Cardiovascular Medicine, Stony Brook University Health Sciences Center T 16-080, Stony Brook, NY 11794-8171, USA. E-mail: david.brown@stonybrook. edu
Received
2009-10-17T00:00:00
Further Resources
Trending Topic
We are sorry to announce the death of one of our valued editorial board members, Dr Richard Heuser (November 17, 1950–May 23, 2024). Richard R Heuser, MD, FACC, FACP, FESC, MSCAI, was an internationally recognized cardiologist, inventor, educator and author, and was a diplomat of the American Board of Cardiovascular Diseases and the American Board […]
Welcome to the summer issue of Heart International. We are excited to present a collection of insightful articles that delve into various aspects of cardiovascular health and related interventions. This issue encompasses a wide array of topics, from novel treatment ...
Clinically relevant tricuspid regurgitation (TR) is a common disorder, affecting approximately 4% of people 75 years of age or older.1 If left untreated, severe TR results in volume overload and right ventricular remodelling. This eventually leads to symptomatic right-sided heart failure, along ...
In this issue of Heart International, we are delighted to present a collection of insightful articles that encompass a wide spectrum of topics within the field of cardiovascular medicine. As we navigate the landscape of cardiovascular disease, heart failure, preventative ...
For decades, right ventricular pacing (RVP) has been the leading pacing technique and has been proven to be effective in treating patients with symptomatic bradycardia. However, dyssynchrony caused by non-physiological ventricular activation results in pacing-induced cardiomyopathy occurs in approximately 15% of ...
Welcome to the latest issue of Heart International. This edition includes a range of articles on topics showcasing the latest advances in our understanding and treatment of cardiovascular disease. We begin with focus on the hereditary cardiac disorder, hypertrophic cardiomyopathy, ...
A significant proportion of patients with atrial fibrillation (AF) who have a high stroke risk are currently being treated with oral anticoagulation (OAC), including direct oral anticoagulants (DOACs) and vitamin K inhibitors (VKAs).1 It is well known that the increased ...
The American Diabetes Association (ADA) defines prediabetes as glycated haemoglobin (HbA1c) 5.7–6.4% or fasting plasma glucose (FPG) 100–125 mg/dL or 5.6–6.9 mmol/L.1 Patients with prediabetes have up to a 70% chance of developing diabetes and a two-fold higher risk of cardiovascular ...
Welcome to the latest issue of Heart International. Cardiovascular science continues to evolve at an impressive rate, and the range of articles presented here highlights cutting-edge technology and innovation within cardiology. We begin with a commentary by Divaka Perera on ...
Welcome to the latest issue of Heart International. We are delighted to bring you another excellent issue, full of the varied and expert articles that you can expect from our authors. We begin with some exciting news. We are delighted ...
Welcome to the latest issue of Heart International. The global coronavirus disease 2019 (COVID-19) pandemic has presented numerous challenges that have altered all areas of health care, including cardiology. Despite these challenges, the past year has shown significant innovation across the ...
Available evidence from randomized studies suggests that most bifurcation lesions are best managed with a provisional stenting (PS) approach, as this is associated with fewer complications, simpler procedures and better outcomes, compared with elective double stenting.1–6 However, the Achilles’ heel ...
The first coronary stent was implanted by Sigwart and Puel in 1986.1 Coronary stents were initially used to treat failure of balloon angioplasty treatment, i.e. as bail-out for acute vessel closure (due to dissections) or restenosis (due to elastic recoil). ...
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
